Editas Medicine Inc expected to post a loss of 70 cents a share - Earnings Preview

Editas Medicine

05/08/2024 15:34

* Editas Medicine Inc  EDIT.OQ   EDIT.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 7
for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 76.1% increase in revenue to $5.083 million from $2.89 million
a year ago, according to the mean estimate from 12 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Editas Medicine Inc is
for a
loss of 70 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Editas
Medicine
Inc is $14.00​, above​ its last closing price of $5.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.66       -0.66      -0.76     Missed  -14.3
 Dec. 31 2024  -0.60       -0.54      -0.23     Beat    57.6
 Sep. 30 2023  -0.56       -0.57      -0.55     Beat    3.2​
 Jan. 1 0001   -0.76       -0.76      -0.56     Beat    26.6
 ​​Mar.        -0.78       -0.78      -0.71     Beat    9.4
 31 2023                                                
 Dec. 31 2022  -0.80       -0.80      -0.88     Missed  -9.7​
 Sep. 30 2022  -0.83       -0.87      -0.81     Beat    6.8
 Jan. 1 0001   -0.81       -0.82      -0.78     Beat    5.1
 This summary was machine generated August 5 at 14:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)